Acelyrin

ACELYRIN forms a scientific and patient advisory board to guide the Phase 3 development of lonigutamab for Thyroid Eye Disease (TED), targeting a 2025 start. Lonigutamab, a subcutaneous IgG1 monoclonal antibody, shows promise for improved treatment outcomes in TED, a vision-threatening autoimmune condition.

Acelyrin's global phase 3 trial of izokibep in moderate-to-severe HS showed significant, clinically meaningful responses by 12 weeks, to be presented at the 2024 EADV in Amsterdam. Izokibep, a small protein therapeutic inhibiting IL-17A, is also under evaluation for PsA and noninfectious uveitis, though Acelyrin has discontinued internal development in HS and PsA.

Terry Chrisomalis, a Biotech sector private investor with an Applied Science background, runs Biotech Analysis Central, offering 600+ articles, a model portfolio, live chat, and analysis for informed Healthcare investing. No positions held in mentioned companies, and no compensation received beyond Seeking Alpha.

ACELYRIN to present positive Phase 3 izokibep trial results for moderate-to-severe hidradenitis suppurativa at the 2024 European Academy of Dermatology and Venereology.

ACELYRIN, INC. announced positive Phase 3 trial results for izokibep in treating moderate-to-severe hidradenitis suppurativa, to be presented at the 2024 European Academy of Dermatology and Venereology. Izokibep, a novel IL-17A inhibitor, showed significant efficacy by week 12, potentially supporting regulatory approval.

Latigo Biotherapeutics appoints Tim Lugo as CFO and adds Beth Seidenberg and Jim Tananbaum to its board, aiming to advance non-opioid pain medicine development.

Acelyrin's izokibep phase III trial for HS met its primary endpoint; refocused pipeline strategy prioritizes lonigutamab for TED. Verrica's phase II study for basal cell carcinoma showed promising results, yet stock plunged. US Fed Circuit reinstated Viberzi patents. Ascentage advances lisaftoclax into fourth phase III for MDS treatment.

ACELYRIN's Phase 3 trial of izokibep for hidradenitis suppurativa met its primary endpoint, HiSCR75 at 12 weeks. The company prioritizes lonigutamab development for thyroid eye disease, with Phase 3 trials planned for Q1 2025. A 33% workforce reduction aligns with strategic shifts, extending cash runway to mid-2027.